(13-087) Assessing appropriate use of pertuzumab and trastuzumab-containing product reloading doses after treatment delays and their effect on outcomes in metastatic HER2-positive breast cancer

Wednesday, December 10, 2025

3:15 PM - 4:15 PM

Location: Bayside A, Level 1

Residency Program: University of Tennessee Medical Center
Residency Program Type: PGY2 (Oncology Pharmacy)
Residency Program Location: Tennessee

Co-Author(s): Stephen Aiken, Courtney Mallon, Ashley Mull, Brandon Rensing

Primary Author(s)

Trevyn Flanders, PharmD

PGY2 Oncology Pharmacy Resident
University of Tennessee Medical Center